Exelixis Files Patent Complaint Against Cipla's Cancer Treatment
By Sabela Ojea
Exelixis has filed a complaint for an alleged patent infringement against Cipla and its abbreviated new drug application that is now pending with the Food and Drug Administration.
The company said on Friday that it's seeking an order to make the effective date of any FDA approval of Cipla's abbreviated new drug application after the expiration of a number of its patents, the latest of which expires on Feb. 10, 2032.
Exelixis is also requesting and equitable relief enjoining Cipla from infringing its patents, the company said.
Cipla's abbreviated new drug application now requests approval to market generic versions of its anti-cancer treatment Cabometyx in tablets with 20 milligrams and 40 milligrams dosage strengths prior to the expiration of some patents.
The company on Thursday filed the complaint in the U.S. District Court for the District of Delaware.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
May 10, 2024 17:18 ET (21:18 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Morningstar’s Guide to Investing in Stocks
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst